Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma

Journal of Surgical Oncology

Volumn 107, Issue 7, 2013, Pages 758-761

  Wang, Wei ^a,b   Qiu, Jianxin ^a   Liu, Zhihong ^a   Zeng, Yigang ^a   Fan, Jie ^a   Liu, Yong ^a   Guo, Yifeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

bladder cancer; immunohistochemistry; prognosis; RING box protein 1 (RBX1)

Indexed keywords

RBX1 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER TRANSITIONAL CELL CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84878289488     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23317     Document Type: Article

References (18)

1. Jacobs BL, Lee CT, Montie JE:, Bladder cancer in 2010: How far have we come ? CA Cancer J Clin 2010; 60: 244-272.
2. Fangliu GYL:, Changing status of genitourinary cancer in recent 50 years. Chin J Urol 2002; 23: 88-90.
3. Soloway MS, Sofer M, Vaidya A:, Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-1583.
4. Nakayama KI, Nakayama K:, Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
5. Petroski MD, Deshaies RJ:, Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
6. Yi Sun MT, Duan H, Swaroop M:, SAG/ROC/Rbx/Hrt, a Zinc RING finger gene family: Molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 2001; 3: 635-650.
7. Tan M, Davis SW, Saunders TL, et al.: RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proc Natl Acad Sci 2009; 106: 6203-6208.
8. Wei D, Sun Y:, Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: The role in cancer and as cancer targets. Genes Cancer 2010; 1: 700-707.
9. Jia L, Sun Y:, SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 2011; 11: 347-356.
10. Jia L, Soengas MS, Sun Y:, ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009; 69: 4974-4982.
11. Nai G, Marques M:, Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. Pathol Res Pract 2011; 207: 174-181.
12. Mitra AP, Cote RJ:, Molecular pathogenesis and diagnostics of bladder cancer. Ann Rev Pathol Mech Dis 2009; 4: 251-285.
13. Stein JP GD, Grossfeld GD, et al.: Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-1079.
14. Rabbani F, Koppie TM, Charytonowicz E, et al.: Prognostic significance of p27Kip1 expression in bladder cancer. BJU Int 2007; 100: 259-263.
15. Chu IM, Hengst L, Slingerland JM:, The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
16. Baud V, Karin M:, Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
17. Horiguchi Y, Kuroda K, Nakashima J, et al.: Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells. Exp Rev Anticancer Ther 2003; 3: 793-798.
18. Muerkoster S:, Increased expression of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005; 65: 1316-1324.